Caroline Swift, Monica S Frazer, Noelle N Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J Dunn, Josh Noone, Mico Guevarra
INTRODUCTION: The treatment landscape for type 2 diabetes mellitus (T2DM) is complex and constantly evolving, and real-world evidence of prescribing patterns is limited. The objectives of this study were to characterize lines of therapy (LOTs), calculate the length of time spent on each LOT, and identify the reasons for the LOT end among patients who initiated oral semaglutide for T2DM. METHODS: This retrospective, claims-based study included commercial and Medicare Advantage adults with T2DM...
May 9, 2024: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders